XBiotech Inc.

NASDAQ:XBIT

Biotechnology

Healthcare
$1.73 -0.84%

-$0.02 today

Market cap
$52.74M
Beta
0.84
P/E (TTM)
-1.8
EPS (TTM)
-$1.32
52W Low $2.09High $3.61

Volume 0.06M

Average 0.03M

XBIT Long-term Debt

Borrowings due after more than one year.

XBiotech Inc.NASDAQ: XBIT

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt remains negative

Q1 FY2026 long-term debt was $0, compared with $0 a year earlier.

Context

  • Long-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Long-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Long-term Debt vs competitors

How XBIT compares with its peers on the latest reported figures

  • XBIT's Mar 2026 long-term debt of $0 is the 7th highest of the 9 companies compared; the peer median is $705.72K.
  • Long-term debt amounts to 0.0% of total assets for XBIT, versus a peer median of 1.3%.
XBIT Competitors Peer median
Long-term Debt for XBIT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
FBIOFortress Biotech, Inc.Mar 2026$36.88M -34.6%-13.9%10.3%
TCRXTScan Therapeutics, Inc.Mar 2026$32.65M +1.5%+3.6%16.2%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$1.26M ——1.2%
ADAGAdagene Inc.Dec 2025$1.14M +172.7%-56.8%1.5%
GANXGain Therapeutics, Inc.Mar 2026$273.27K -13.1%-15.4%1.5%
NTRBNutriband Inc.Apr 2026$29.83K -43.3%-29.1%0.4%
XBITXBiotech Inc.Mar 2026$0 ——0.0%
RLMDRelmada Therapeutics, Inc.Mar 2026$0 ——0.0%
ACETAdicet Bio, Inc.Mar 2026$0 ——0.0%
Peer median (excluding XBIT) $705.72K-13.1%-15.4%1.3%

Competitors are the stored peer set for XBIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents236.98M157.31M200.02M172.68M125.55M
Short-term Investments060.17M000
Net Receivables8.95M1.76M935K858K360K
Inventory00000
Other Current Assets0601K760K1.03M1.04M
Total Current Assets246.87M219.84M201.72M174.57M126.95M
Property, Plant & Equipment (Net)28.31M26.26M24.9M24.53M23.13M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets1.09M1.66M000
Other Non-current Assets(1.09M)(1.66M)000
Total Non-current Assets28.31M26.26M24.9M24.53M23.13M
Total Assets275.18M246.1M226.62M199.09M150.08M
Account Payables2.07M2.41M2.52M2.22M1.54M
Short-term Debt00010.25M0
Tax Payables10K55K83K1.72M76K
Deferred Revenue00000
Other Current Liabilities904K1.17M562K611K5.18M
Total Current Liabilities3.45M4.07M6.1M15.11M7.93M
Long-term Debt00000
Deferred Tax Liabilities873K59K005K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.47M1.58M1.67M1.72M1.8M
Total Non-current Liabilities2.34M1.64M1.67M1.72M1.8M
Total Liabilities5.79M5.7M7.77M16.83M9.73M
Common Stock262.26M267.33M271.15M273.11M276.73M
Retained Earnings5.15M(27.75M)(52.31M)(90.84M)(136.38M)
Accumulated OCI1.97M826K000
Other Stockholders Equity00000
Minority Interest00000
Total Equity269.39M240.4M218.85M182.27M140.35M
Total Debt00010.25M0
Net Debt(236.98M)(157.31M)(200.02M)(162.43M)(125.55M)

XBiotech Inc.

NASDAQ:XBIT

Intrinsic Alpha fair value

Locked

Current Price

$1.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.